ReviewFrontiers in immunology2026
Beyond inflammation: metabolic implications of biological and TsDMARD therapies in dermatologic and rheumatologic diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.Journal of translational medicine · 2026Review
- Methotrexate Exposure and Inflammatory-Metabolic Biomarker Networks in Hospitalized Patients with Psoriasis: A Network Analysis Approach.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) have transformed the management of chronic inflammatory diseases. Yet their therapeutic impact extends beyond cytokine suppression, influencing systemic metabolic pathways that are increasingly recognised as central to immune regulation. This narrative review examines the immunometabolic effects of major biologic and targeted synthetic DMARD classes used in dermatologic and rheumatologic diseases. We synthesise evidence on how these agents modulate insulin sensitivity, lipid metabolism, adipokine profiles, mitochondrial function, and adipose-tissue inflammation thereby shaping cardiovascular and metabolic risk. TNF inhibitors show heterogeneous metabolic effects, whereas IL-6 blockade and JAK inhibition consistently improve glycemic parameters despite inducing characteristic lipid changes. IL-17 and IL-23 inhibitors may attenuate adipose inflammation, while TYK2 inhibitors appear metabolically neutral. Through integration of mechanistic insights and clinical data, this review highlights the need to incorporate metabolic phenotyping into therapeutic decision-making. Understanding the distinct metabolic fingerprints of DMARDs may enable more precise patient stratification and support emerging combinatorial strategies with metabolic agents such as GLP-1 receptor agonists and SGLT2 inhibitors. These perspectives underscore the translational importance of viewing DMARD therapies not only as immunomodulators but also as systemic metabolic regulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.